A Phase II Study of Palbociclib Plus Fulvestrant for Pretreated Patients With ER+/HER2- Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Fulvestrant (Primary) ; Palbociclib (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms PYTHIA
- 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress
- 06 Jun 2016 Status changed from not yet recruiting to recruiting.
- 22 Jan 2016 Planned initiation date changed from 1 Jan 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.